PCRX
HealthcarePacira BioSciences, Inc. · Drug Manufacturers - Specialty & Generic · $920M
What is Pacira BioSciences, Inc.?
Pacira BioSciences focuses on non-opioid pain management and regenerative health solutions for patients and healthcare providers across the United States. The company has built its commercial portfolio around alternatives to traditional opioid therapies, addressing a significant unmet need in post-surgical and chronic pain care.
Pacira generates revenue primarily through the sale of three commercially available products targeting pain management without opioids. Its flagship injectable suspension is used in nerve blocks for post-surgical pain control, while a second product delivers extended-release corticosteroid therapy for joint pain. A handheld cryoanalgesia device rounds out the portfolio by using controlled cold temperature to temporarily disrupt nerve signaling. The company also maintains a proprietary drug delivery platform based on multivesicular liposome technology.
Incorporated in 2006 and headquartered in Tampa, Florida, Pacira operates at the intersection of specialty pharmaceuticals and medical devices.
- EXPAREL — bupivacaine liposome injectable suspension for post-surgical nerve blocks
- ZILRETTA — extended-release triamcinolone acetonide injectable for joint pain
- iovera system — handheld cryoanalgesia device for non-opioid nerve treatment
- Multivesicular liposome (MVL) drug delivery platform
Is PCRX a Good Stock to Buy?
UQS Score rates PCRX as Below Average overall, reflecting meaningful challenges across several key dimensions of stock quality.
Among the brighter spots in the profile, Valuation comes in as Attractive — meaning the stock may be priced at a discount relative to its fundamentals. The Growth and Risk pillars both register as Neutral, suggesting the business is neither accelerating sharply nor facing acute financial distress at this time.
Both the Quality and Moat pillars are rated Weak, pointing to below-average business durability and limited competitive insulation — factors that weigh heavily on the composite score.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does PCRX pay dividends?
No — Pacira BioSciences, Inc. does not currently pay a dividend.
Pacira BioSciences does not currently pay a dividend. For a specialty pharmaceutical company at this stage, retaining capital to fund commercial operations, product development, and potential pipeline expansion is the typical approach. Income-focused investors should factor this into their assessment of PCRX.
When does PCRX report earnings?
Pacira BioSciences reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Revenue trends have been shaped largely by adoption of its flagship injectable product and the integration of acquired assets. Profitability has remained a work in progress, with the company balancing commercial investment against cost discipline.
For the most recent quarter's results and guidance, visit Pacira BioSciences' investor relations page directly.
PCRX Price History
-59.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Pacira BioSciences, Inc.?
Based on Pacira BioSciences, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
PCRX Long-term Outlook
The fundamental outlook for PCRX is mixed. A Neutral Growth pillar suggests the business is not in decline but has yet to demonstrate a clear acceleration in revenue or earnings trajectory. The Neutral Risk rating indicates the balance sheet and operational profile are manageable, though the Weak Quality and Moat scores limit confidence in sustained long-term compounding. The Attractive Valuation label may reflect the market's skepticism about durable competitive advantages rather than a straightforward opportunity.
Growth drivers
- Continued adoption of non-opioid pain management alternatives in surgical settings
- Potential label expansions or new indications for existing commercial products
- Growing policy and clinical focus on reducing opioid dependency in post-surgical care
Key risks
- Weak Moat rating signals limited pricing power and vulnerability to competition
- Weak Quality pillar raises questions about earnings consistency and capital efficiency
- Specialty pharmaceutical revenue concentration in a small number of products
PCRX vs Peers
Pacira operates in a competitive specialty pharmaceutical and pain management landscape alongside several focused peers.
Amphastar competes across a broader injectable drug portfolio, with a manufacturing-focused model that differs from Pacira's branded non-opioid positioning.
Collegium centers its business on abuse-deterrent opioid formulations, making it a philosophically distinct competitor in the pain management category.
Cronos operates in the cannabinoid space and represents an alternative non-opioid pain and wellness approach, though from a very different regulatory and commercial framework.
Frequently Asked Questions
What does Pacira BioSciences do?
Pacira BioSciences develops and commercializes non-opioid pain management and regenerative health products. Its portfolio includes an injectable nerve block suspension, an extended-release joint pain treatment, and a handheld cryoanalgesia device. The company also maintains a proprietary liposome-based drug delivery platform used across its product development efforts.
Does PCRX pay dividends?
Pacira BioSciences does not currently pay a dividend. The company retains capital to support its commercial operations and ongoing development activities. Investors seeking regular income should note that PCRX is not structured as a dividend-paying stock at this time.
When does PCRX report earnings?
Pacira BioSciences follows a standard quarterly earnings reporting schedule. Specific dates are announced in advance through the company's investor relations channels. For the most up-to-date schedule, check the Pacira BioSciences investor relations page rather than relying on third-party estimates.
Is PCRX a good stock to buy?
UQS Score rates PCRX as Below Average, driven by Weak scores on both Quality and Moat. The Valuation pillar is Attractive, and Growth and Risk are Neutral. Whether that combination suits your portfolio depends on your risk tolerance and investment goals. The full pillar breakdown is available to UQS Pro members.
Is PCRX overvalued?
Based on the UQS framework, PCRX carries an Attractive Valuation rating, suggesting the stock may be priced at a discount relative to its fundamentals. However, an attractive price does not offset the Weak Quality and Moat scores — value without durability carries its own risks.
How does PCRX compare to its competitors?
Pacira's non-opioid focus differentiates it from peers like Collegium, which leans on abuse-deterrent opioids, and Amphastar, which operates a broader injectable generics model. Each company targets pain management from a different angle. The UQS Score platform allows side-by-side quality comparisons across these tickers for Pro members.
What is PCRX's market cap bracket?
Pacira BioSciences is classified as a small-cap stock. This places it in a segment of the market that can offer growth potential but typically carries higher volatility and liquidity risk compared to large- or mega-cap peers in the healthcare sector.
Who founded Pacira BioSciences?
Pacira was incorporated in 2006 and built around a team with deep expertise in liposome-based drug delivery. The company was formerly known as Pacira Pharmaceuticals before rebranding in 2019. Detailed founding history is publicly available through the company's official disclosures and SEC filings.
Is PCRX a long-term quality investment?
As a long-term quality indicator, the UQS Score for PCRX is Below Average. The Weak Moat and Quality pillars suggest limited competitive durability over time. While the Attractive Valuation may appeal to contrarian investors, sustained long-term compounding typically requires stronger scores across Quality and Moat. Pro members can view the complete analysis.
What is the main competitive advantage of Pacira BioSciences?
Pacira's primary differentiator is its proprietary multivesicular liposome drug delivery technology, which enables extended-release formulations without altering a drug's molecular structure. Its commercial focus on non-opioid pain management also aligns with growing clinical and regulatory pressure to reduce opioid use in surgical settings. However, the UQS Moat pillar rates this advantage as Weak.
What sector does PCRX belong to?
Pacira BioSciences operates in the Healthcare sector, specifically within specialty pharmaceuticals and medical devices. Its products sit at the intersection of drug delivery innovation and non-opioid pain management, a niche that has attracted increasing attention from both clinicians and policymakers.
Unlock Full PCRX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access complete financial metrics and trend data
- ✓Compare PCRX side-by-side with sector peers
- ✓See the full Quality and Moat breakdown in detail
- ✓Track score changes over time with Pro alerts
- ✓Explore curated screeners for healthcare small-caps
Pro Analysis
PCRX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 7, 2026 | 47.3 | 36.8 | 26.0 | 52.0 | 47.7 | 93.7 | 0.0 |
| May 4, 2026 | 47.3 | 36.8 | 26.0 | 52.0 | 47.7 | 93.5 | -0.1 |
| May 2, 2026 | 47.4 | 36.8 | 26.0 | 52.5 | 47.7 | 93.5 | +0.1 |
| Apr 26, 2026 | 47.3 | 36.8 | 26.0 | 51.9 | 47.7 | 93.5 | 0.0 |
| Apr 19, 2026 | 47.3 | 36.8 | 26.0 | 52.0 | 47.7 | 93.5 | 0.0 |
| Apr 18, 2026 | 47.3 | 36.8 | 26.0 | 52.0 | 47.7 | 93.7 | -0.9 |
| Apr 9, 2026 | 48.2 | 36.8 | 26.0 | 52.0 | 47.7 | 100.0 | -0.1 |
| Apr 2, 2026 | 48.3 | 36.8 | 26.0 | 52.1 | 47.7 | 100.0 | — |
PCRX — Pillar Breakdown
Quality
— 36.7/100 (25%)Pacira BioSciences, Inc. has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 52.1/100 (20%)Pacira BioSciences, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 50.2/100 (15%)Pacira BioSciences, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 93.5/100 (15%)Pacira BioSciences, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 26/100 (25%)Pacira BioSciences, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PCRX.
Score Composition
Financial Data
More Stock Analysis
How is the PCRX UQS Score Calculated?
The UQS (Unified Quality Score) for Pacira BioSciences, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Pacira BioSciences, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Pacira BioSciences, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.